LabCorp 2006 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2006 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 56

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56

Breast cancers vary significantly in their
aggressiveness, likelihood of recurrence
and response to treatment. Modern
oncology care requires the physician
to customize for each patient a thera-
peutic regimen – which may include
chemotherapy, radiation or hormone
therapy – that provides the best
prospects to cure the disease.
Highly sensitive tests, such as
assays measuring the HER2/neu protein,
can give critical prognostic information
to clinicians, and help to predict the
effectiveness of certain breast cancer
therapies. Hormone receptor analysis
and studies of proliferation markers
also play critical roles in helping
clinicians to select the best weapons
to fight the spread or recurrence of
tumors. More accurate and sensitive
testing is playing a significant role in
accelerating progress against breast
cancer and other malignancies.
TEST PROFILE:
ONCOLOGY
THERAPY SELECTION
A test that becomes
routine can virtually
eradicate a disease.
enhance knowledge
...........................................
....................................................